UCLA Hematology/Oncology - Marina del Rey — Marina del Rey, California

UCLA Hematology/Oncology - Marina del Rey is a clinical research site located in Marina del Rey, California, United States 90292.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

UCLA Hematology/Oncology - Marina del Rey has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer.

Sponsors: Pfizer.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Marina del Rey

Browse all research sites in California · View every site in Marina del Rey

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for UCLA Hematology/Oncology - Marina del Rey?

UCLA Hematology/Oncology - Marina del Rey has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has UCLA Hematology/Oncology - Marina del Rey conducted?

UCLA Hematology/Oncology - Marina del Rey has 1 clinical trials on record, with 1 currently active. Their work covers Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer.

Is UCLA Hematology/Oncology - Marina del Rey accredited by Crixeo Clinical Trials?

UCLA Hematology/Oncology - Marina del Rey has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about UCLA Hematology/Oncology - Marina del Rey?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.